Kappa opioid receptors (KORs) mediate many effects of opioid drugs, including analgesia, dysphoria and water diuresis. Kappa agonists may be useful as analgesics, water diuretics and antipruritic agents. Repeated or continuous administration of kappa agonists leads to tolerance, part of which can be accounted for at the receptor level. The applicant's long-term objectives are to understand at the molecular level the biochemical events that occur following chronic exposure to opioid drugs. The following are the hypotheses for proposed studies. Following chronic exposure to an agonist, the human KOR undergoes desensitization, sequestration and down-regulation. Desensitization is due to agonist- induced phosphorylation of the receptor by G protein-coupled receptor kinases (GRKs) followed by binding of beta-arrestin, leading to the uncoupling of the receptor from G proteins. Binding of beta-arrestin to phosphorylated receptors initiates receptor sequestration into cells via clathrin-coated vesicles. Some internalized receptors are degraded resulting in down-regulation. Certain amino acid residues or sequence motifs in the receptor play important roles in these. Kappa agonist treatment regulates levels of certain regulators of G protein signaling (RGS) proteins, which are negative regulators of the KOR signaling.
Specific aims are as follows. (1) To determine whether there are differences between the human and rat KORs in agonist-induced desensitization, sequestration, down-regulation and phosphorylation. (2) To determine the roles of GRKs, protein kinase A and protein kinase C in agonist-induced desensitization and phosphorylation of the human KOR by expression of GRKs, beta-arrestin GRK mutants and activation and inhibition of protein kinases A and C. (3) To determine the amino acid residue(s) of the human KOR that are phosphorylated upon desensitization by site-directed mutagenesis studies. (4) To investigate molecular mechanisms of agonist-induced sequestration of the kappa receptor by expression of beta-arrestin and dynamin mutants and to determine the motif important for sequestration by site-directed mutagenesis studies. (5) To determine the amino acid residue(s) of the kappa receptor that are important in down-regulation by site-directed mutagenesis studies. (6) To determine whether RGS proteins regulate signal transduction of the KOR. Elucidation of the mechanisms involved in agonist-induced regulation of the KOR will lead to a better understanding of tolerance to kappa agonist, which will help in the development of better kappa agonists as useful drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA011263-04
Application #
6497804
Study Section
Pharmacology A Study Section (PHRA)
Program Officer
Lin, Geraline
Project Start
1999-02-15
Project End
2004-01-31
Budget Start
2002-02-15
Budget End
2004-01-31
Support Year
4
Fiscal Year
2002
Total Cost
$215,883
Indirect Cost
Name
Temple University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Chen, Yong; Chen, Chongguang; Kotsikorou, Evangelia et al. (2009) GEC1-kappa opioid receptor binding involves hydrophobic interactions: GEC1 has chaperone-like effect. J Biol Chem 284:1673-85
Wang, Y; Dun, S L; Huang, P et al. (2006) Distribution and ultrastructural localization of GEC1 in the rat CNS. Neuroscience 140:1265-76
Xu, Wei; Yoon, Su-In; Huang, Peng et al. (2006) Localization of the kappa opioid receptor in lipid rafts. J Pharmacol Exp Ther 317:1295-306
Lalovic, Bojan; Kharasch, Evan; Hoffer, Christine et al. (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79:461-79
Wang, Yulin; Tang, Kang; Inan, Saadet et al. (2005) Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312:220-30
Xu, Wei; Campillo, Mercedes; Pardo, Leonardo et al. (2005) The seventh transmembrane domains of the delta and kappa opioid receptors have different accessibility patterns and interhelical interactions. Biochemistry 44:16014-25
Chen, Chongguang; Li, Jin; Bot, George et al. (2004) Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor. Eur J Pharmacol 483:175-86
Huang, Peng; Steplock, Deborah; Weinman, Edward J et al. (2004) kappa Opioid receptor interacts with Na(+)/H(+)-exchanger regulatory factor-1/Ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) to stimulate Na(+)/H(+) exchange independent of G(i)/G(o) proteins. J Biol Chem 279:25002-9
Wang, Yulin; Li, Jian-Guo; Huang, Peng et al. (2003) Differential effects of agonists on adenylyl cyclase superactivation mediated by the kappa opioid receptors: adenylyl cyclase superactivation is independent of agonist-induced phosphorylation, desensitization, internalization, and down-regulation. J Pharmacol Exp Ther 307:1127-34
Szabo, Imre; Wetzel, Michele A; Zhang, Ning et al. (2003) Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization. J Leukoc Biol 74:1074-82

Showing the most recent 10 out of 24 publications